Silk Road Medical Stock Forecast, Price & News

Silk Road Medical's stock was trading at $37.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SILK shares have increased by 87.4% and is now trading at $69.61.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Silk Road Medical in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Silk Road Medical.

Silk Road Medical is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Silk Road Medical.

Silk Road Medical Inc (NASDAQ:SILK) announced its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.38) by $0.06. The firm earned $15.10 million during the quarter, compared to analysts' expectations of $12.37 million. Silk Road Medical had a negative net margin of 52.69% and a negative return on equity of 43.15%. The company's revenue for the quarter was up .7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.42) EPS.
View Silk Road Medical's earnings history.

4 brokerages have issued 1 year price objectives for Silk Road Medical's stock. Their forecasts range from $54.00 to $60.00. On average, they expect Silk Road Medical's share price to reach $56.75 in the next twelve months. This suggests that the stock has a possible downside of 18.5%.
View analysts' price targets for Silk Road Medical.

Silk Road Medical saw a drop in short interest during the month of August. As of August 14th, there was short interest totaling 1,790,000 shares, a drop of 17.5% from the July 30th total of 2,170,000 shares. Based on an average trading volume of 424,700 shares, the days-to-cover ratio is currently 4.2 days. Currently, 5.9% of the shares of the company are short sold.
View Silk Road Medical's Short Interest.

Some companies that are related to Silk Road Medical include Penumbra (PEN), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Hill-Rom (HRC), Globus Medical (GMED), Nevro (NVRO), Haemonetics (HAE), ICU Medical (ICUI), Integra Lifesciences (IART), Inspire Medical Systems (INSP), Inari Medical (NARI), Inovio Pharmaceuticals (INO), NuVasive (NUVA), Shockwave Medical (SWAV) and Merit Medical Systems (MMSI).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Silk Road Medical investors own include Procter & Gamble (PG), Abbott Laboratories (ABT), Cisco Systems (CSCO), Pfizer (PFE), CSX (CSX), Honeywell International (HON), Raytheon Technologies (RTX), Veeva Systems (VEEV), Alibaba Group (BABA) and Edwards Lifesciences (EW).

(SILK) raised $75 million in an initial public offering (IPO) on Thursday, April 4th 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and BMO Capital Markets and Stifel were co-managers.

Silk Road Medical trades on the NASDAQ under the ticker symbol "SILK."

Silk Road Medical's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.38%), Wasatch Advisors Inc. (8.04%), Jennison Associates LLC (4.88%), Bamco Inc. NY (4.69%), TimesSquare Capital Management LLC (3.35%) and Victory Capital Management Inc. (2.93%). Company insiders that own Silk Road Medical stock include Andrew S Davis, Erica J Rogers, Lucas W Buchanan, Pincus & Co Warburg, Richard Ruedy and X Finance LP Wp.
View institutional ownership trends for Silk Road Medical.

SILK stock was sold by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, HighTower Advisors LLC, Nicholas Investment Partners LP, Peregrine Capital Management LLC, Rhenman & Partners Asset Management AB, Chartwell Investment Partners LLC, Schonfeld Strategic Advisors LLC, and Sei Investments Co.. Company insiders that have sold Silk Road Medical company stock in the last year include Andrew S Davis, Erica J Rogers, Lucas W Buchanan, Pincus & Co Warburg, and Richard Ruedy.
View insider buying and selling activity for Silk Road Medical.

SILK stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Vanguard Group Inc., State of Wisconsin Investment Board, Frontier Capital Management Co. LLC, Jennison Associates LLC, Perceptive Advisors LLC, Summit Partners Public Asset Management LLC, and TimesSquare Capital Management LLC.
View insider buying and selling activity for Silk Road Medical.

Shares of SILK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SILK stock can currently be purchased for approximately $69.61.

Silk Road Medical has a market capitalization of $2.34 billion and generates $63.35 million in revenue each year. The company earns $-52,420,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Silk Road Medical employs 176 workers across the globe.

The official website for Silk Road Medical is www.silkroadmed.com.

Silk Road Medical's mailing address is 1213 INNSBRUCK DR., SUNNYVALE CA, 94089. The company can be reached via phone at 408-720-9002 or via email at [email protected]